{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:52Z","timestamp":1784764852664,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.maturitas.2026.108998","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:08:24Z","timestamp":1779721704000},"page":"108998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of breast risk at menopause: what impact on the use of menopausal hormone therapy?"],"prefix":"10.1016","volume":"211","author":[{"given":"M\u00e1rcio Alexandre Hip\u00f3lito","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2026.108998_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17512433.2023.2219056","article-title":"Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts\u2019 perspective","volume":"16","author":"Rozenberg","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM198908033210505","article-title":"The risk of breast cancer after estrogen and estrogen-progestin replacement","volume":"321","author":"Bergkvist","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108998_bb0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-8587(25)00394-8","article-title":"Menopausal hormone treatment and breast cancer","volume":"14","author":"Gompel","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2026.108894","article-title":"Menopausal hormone therapy and breast cancer: balancing risks and benefits","volume":"208","author":"Bollam","year":"2026","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.108998_bb0030","doi-asserted-by":"crossref","first-page":"8EP","DOI":"10.1016\/j.maturitas.2023.04.271","article-title":"Reappraising 21 years of the WHI study: putting the findings in context for clinical practice","volume":"174","author":"Stute","year":"2023","journal-title":"Maturitas"},{"issue":"11","key":"10.1016\/j.maturitas.2026.108998_bb0035","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an endocrine society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"Clin Endocrinol Metab."},{"key":"10.1016\/j.maturitas.2026.108998_bb0040","article-title":"Efficacy and safety of antibody drug conjugates in previously treated hormone receptor positive HER2 negative (or low) metastatic breast cancer-a systematic review and meta-analysis","author":"Huang","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00228-024-03644-2","article-title":"Progress of PD-1\/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors","volume":"80","author":"Zhao","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0050","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","article-title":"Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","volume":"13","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/13697137.2025.2585487","volume":"28","author":"Panay","year":"2025","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.108998_bb0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7150\/ijbs.8579","article-title":"BRCA1 and estrogen\/estrogen receptor in breast cancer: where they interact?","volume":"10","author":"Wang","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.maturitas.2026.108998_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-46028-5","article-title":"Endogenous and environmental factors that induce DNA replication defects and genomic instability in ER-negative heterozygous BRCA1 cells","volume":"16","author":"Deshpande","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.maturitas.2026.108998_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/gcc.10321","article-title":"Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A","volume":"39","author":"Mote","year":"2004","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13058-019-1214-0","article-title":"BRCA1 mutation influences progesterone response in human benign mammary organoids","volume":"21","author":"Davaadelger","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2026.108998_bb0085","doi-asserted-by":"crossref","first-page":"45317","DOI":"10.18632\/oncotarget.9638","article-title":"Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations","volume":"7","author":"Communal","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.maturitas.2026.108998_bb0090","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/aje\/kwac116","article-title":"Birth cohort effects in breast cancer incidence: global patterns and trends","volume":"191","author":"Chen","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-024-01766-0","article-title":"Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea","volume":"26","author":"Nabila","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108998_bb0100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1470-2045(25)00156-1","article-title":"Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records","volume":"26","author":"Hassan","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32120705","article-title":"The risk of breast cancer according to mutation type and position in carriers of a pathogenic variant in BRCA1","volume":"32","author":"Kotsopoulos","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2025.11.004","article-title":"Association between type and location of germline BRCA1\/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study","volume":"37","author":"Toss","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0115","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2026.108998_bb0120","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaoncol.2025.3875","article-title":"Pathogenic variants, family history, and cumulative risk of breast cancer in US women","volume":"11","author":"O\u2019Brien","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa044383","article-title":"Benign breast disease and the risk of breast cancer","volume":"353","author":"Hartmann","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0130","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0135","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1186\/s12885-024-12641-8","article-title":"Non-genetic factors and breast cancer: an umbrella review of meta-analyses","volume":"24","author":"Yiallourou","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0140","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(05)70390-9","article-title":"Mammographic breast density as an intermediate phenotype for breast cancer","volume":"6","author":"Boyd","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0174","article-title":"Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density","volume":"4","author":"Brentnall","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0150","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-20-0358","article-title":"Breast cancer surveillance consortium, breast cancer population attributable risk proportions associated with body mass index and breast density by race\/ethnicity and menopausal status","volume":"29","author":"Bissell","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.maturitas.2026.108998_bb0155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10549-017-4347-9","article-title":"Association between lifestyle, menstrual\/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease","volume":"165","author":"Arthur","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.108998_bb0160","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/sj.bjc.6600596","article-title":"Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease","volume":"87","author":"Hamajima","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-015-3628-4","article-title":"Active and passive smoking and risk of breast cancer: a meta-analysis","volume":"154","author":"Macacu","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.108998_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108985","article-title":"Carcinogenic industrial air pollution and postmenopausal breast cancer risk in the National Institutes of Health AARP Diet and Health Study","volume":"191","author":"Madrigal","year":"2024","journal-title":"Environ. Int."},{"key":"10.1016\/j.maturitas.2026.108998_bb0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.24.00418","article-title":"Air pollution and breast cancer incidence in the multiethnic cohort study","volume":"43","author":"Wu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2019.06.007","article-title":"Airborne mammary carcinogens and breast cancer risk in the Sister Study","volume":"130","author":"Niehoff","year":"2019","journal-title":"Environ. Int."},{"key":"10.1016\/j.maturitas.2026.108998_bb0185","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/biomedicines13112774","article-title":"Endocrine disruptors and breast cancer: a comprehensive review","volume":"13","author":"Czaczkowska","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.maturitas.2026.108998_bb0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-025-02197-1","article-title":"The aetiology of breast cancer subtypes: results from the Million Women Study","volume":"28","author":"Reeves","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2026.108998_bb0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1878-0261.70158","article-title":"European Code Against Cancer, 5th edition - hormone replacement therapy, other common medical therapies and cancer","volume":"20","author":"Thorat","year":"2026","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0200","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ijc.32846","article-title":"The impact of alcohol consumption and physical activity on breast cancer: the role of breast cancer risk","volume":"147","author":"Rainey","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0205","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1038\/s41467-021-24861-8","article-title":"An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites","volume":"12","author":"Papadimitriou","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.maturitas.2026.108998_bb0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10654-023-01005-4","article-title":"The association of a combined healthy lifestyle with the risk of postmenopausal breast cancer subtypes in the Netherlands Cohort Study","volume":"38","author":"van den Brandt","year":"2023","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0215","series-title":"Breast cancer facts & stats 2025 - incidence, age, survival, & more","year":"2026"},{"key":"10.1016\/j.maturitas.2026.108998_bb0220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1470-2045(18)30902-1","article-title":"10-year performance of four models of breast cancer risk: a validation study","volume":"20","author":"Terry","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0225","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41416-025-03117-y","article-title":"Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population","volume":"133","author":"Ficorella","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0235","article-title":"Screening for familial cancer risk: focus on breast cancer","volume":"105","author":"C","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.108998_bb0240","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/s12885-023-11049-0","article-title":"Association of reproductive risk factors and breast cancer molecular subtypes: a systematic review and meta-analysis","volume":"23","author":"Mao","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0245","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41416-024-02590-1","article-title":"Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway","volume":"131","author":"Stoer","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115340","article-title":"Update of the impact of menopausal hormone therapy on breast cancer risk","volume":"220","author":"Siitonen","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108998_bb0255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/M19-0274","article-title":"Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy","volume":"171","author":"Manson","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0260","first-page":"767","article-title":"\u201cThe 2022 hormone therapy position statement of the North American Menopause Society\u201d Advisory Panel, The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.108998_bb0265","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2026.108998_bb0270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1055-9965.EPI-23-0923","article-title":"Abbreviated score to assess adherence to the 2018 WCRF\/AICR cancer prevention recommendations and risk of cancer in the UK Biobank","volume":"33","author":"Malcomson","year":"2024","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.maturitas.2026.108998_bb0275","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/ije\/dyac238","article-title":"Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types","volume":"52","author":"Byrne","year":"2023","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0280","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaoncol.2016.1025","article-title":"Breast cancer risk from modifiable and nonmodifiable risk factors among White women in the United States","volume":"2","author":"Maas","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0285","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archinternmed.2009.303","article-title":"New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk","volume":"169","author":"Crandall","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0290","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/archinte.166.15.1578","article-title":"Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy","volume":"166","author":"Crandall","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0295","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoae065","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"2024","author":"Panay","year":"2024","journal-title":"Hum. Reprod. Open"},{"key":"10.1016\/j.maturitas.2026.108998_bb0300","doi-asserted-by":"crossref","first-page":"e1678","DOI":"10.1210\/clinem\/dgae480","article-title":"Breast cancer is increased in women with primary ovarian insufficiency","volume":"110","author":"Allen-Brady","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2026.108998_bb0305","article-title":"Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2","author":"Kotsopoulos","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.108998_bb0310","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2026.108998_bb0315","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.24.01146","article-title":"Second primary cancer risks after breast cancer in BRCA1 and BRCA2 pathogenic variant carriers","volume":"43","author":"Allen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108998_bb0320","article-title":"Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)","volume":"14","author":"Simon","year":"2026","journal-title":"Sex. Med. Rev."},{"key":"10.1016\/j.maturitas.2026.108998_bb0325","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.maturitas.2026.108998_bb0330","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa623","article-title":"Approach to managing a postmenopausal patient","volume":"105","author":"Santen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:02:33Z","timestamp":1784761353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226001751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"alternative-id":["S0378512226001751"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108998","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of breast risk at menopause: what impact on the use of menopausal hormone therapy?","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108998"}}